 |
|
Anticoagulant Therapy in Patients Aged 80 Years or More With Atrial FibrillationMore Caution Is Needed
Richard J. Ackermann, MD
Arch Fam Med. 1997;6(2):105-110.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Lackner TE, Battis GN. Use of warfarin for nonvalvular atrial fibrillation in nursing home patients. Arch Fam Med. 1995;4:1017-1026.
FREE FULL TEXT
2. Brechtelsbauer DA. New knowledge, old patients. Arch Fam Med. 1995;4:1014-1016.
FREE FULL TEXT
3. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108:352S-359S.
PUBMED
4. Deantonio HJ, Movahed A. Atrial fibrillation: current therapeutic approaches. Am Fam Physician. 1992;45:2576-2584.
PUBMED
5. Donnan GA. Anticoagulants for atrial fibrillation. Med J Aust. 1992;157:77-78.
PUBMED
6. Dunn M, Blackburn T. Anticoagulant treatment of atrial fibrillation in the elderly. Postgrad Med J. 1992;68(suppl_1):S57-S60.
PUBMED
7. Ramsay LE. Warfarin in chronic atrial fibrillation. Lancet. 1993;341:1376-1377.
PUBMED
8. Silverman ME. To anticoagulate or not to anticoagulate? that is no longer the question. Heart Dis Stroke. 1993;2:461-463.
PUBMED
9. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
FREE FULL TEXT
10. Dalen JE. Atrial fibrillation: reducing stroke risk with low-dose anticoagulation. Geriatrics. 1994;49:24-32.
PUBMED
11. Aronow WS. Atrial fibrillation and thromboembolic stroke. Compr Ther. 1994;20:186-191.
PUBMED
12. O'Connell JE. Warfarin in chronic atrial fibrillation in the elderly. Lancet. 1993;342:48.
PUBMED
13. Singer DE. Overview of the randomized trials to prevent stroke in atrial fibrillation. Ann Epidemiol. 1993;3:563-567.
PUBMED
14. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med. 1994;154:1443-1448.
FREE FULL TEXT
15. Feinberg WM, Blackshear JL, Laupacis A, Kronamal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469-473.
FREE FULL TEXT
16. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration of and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 1996;125:311-323.
FREE FULL TEXT
17. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
FREE FULL TEXT
18. Aronow WS. Correlation of arrhythmias and conduction defects on the resting electrocardiogram with new cardiac events in 1,153 elderly patients. Am J Noninvas Cardiol. 1991;5:88-90.
19. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc. 1996;44:521-523.
PUBMED
20. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc. 1990;65:344-359.
PUBMED
21. Lancaster T. Anticoagulation in patients with atrial fibrillation: atrial fibrillation associated with aging. BMJ. 1993;307:1494.
FREE FULL TEXT
22. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236-241.
PUBMED
23. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995;346:1313-1314.
PUBMED
24. Lundström T, Rydén L. Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med. 1989;225:137-142.
PUBMED
25. Aboaf AP, Wolf PS. Paroxysmal atrial fibrillation: a common but neglected entity. Arch Intern Med. 1996;156:362-367.
FREE FULL TEXT
26. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire Community Stroke Project). BMJ. 1992;305:1460-1465.
FREE FULL TEXT
27. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
PUBMED
28. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin compared to aspirin for prevention of arterial thromboembolism in atrial fibrillation: design and patient characteristics of the Stroke Prevention in Atrial Fibrillation II Study. Cerebrovasc Dis. 1992;2:332-341.
29. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;28:175-179.
30. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation: the Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-1511.
ABSTRACT
31. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
ABSTRACT
32. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
FREE FULL TEXT
33. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrhematic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
ABSTRACT
34. Sudlow C, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ. 1995;311:558-561.
FREE FULL TEXT
35. Rassam SM. Anticoagulation in patients with atrial fibrillation: not safe and not cheap. BMJ. 1993;307:1492.
FREE FULL TEXT
36. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marké LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-1460.
FREE FULL TEXT
37. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-1262.
PUBMED
38. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation: European Atrial Fibrillation Trial (EAFT) Study Group. Stroke. 1995;26:801-806.
FREE FULL TEXT
39. Wilson DB, McBride R. Thromboembolismvs anticoagulation intensity in highrisk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrilliation (SPAF) III Study. Circulation. 1996;94(suppl 1)1-33. Abstract.
FREE FULL TEXT
40. Lancaster TR, Singer DE, Sheehan MA, et al. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial: Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med. 1991;151:1944-1949.
FREE FULL TEXT
41. Connolly S. Stroke prevention in Atrial Fibrillation II Study. Lancet. 1994;343:1509.
PUBMED
42. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
FREE FULL TEXT
43. Fiore LD. Anticoagulation: risks and benefits in atrial fibrillation. Geriatrics. 1996;51(6):22-31.
PUBMED
44. Jerntorp P, Berglund G. Stroke registry in Malmö, Sweden. Stroke. 1992;23:357-361.
FREE FULL TEXT
45. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranialhemorrhage: facts and hypotheses. Stroke. 1995;26:1471-1477.
FREE FULL TEXT
46. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
FREE FULL TEXT
47. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
PUBMED
48. Conti CR. Stroke and atrial fibrillation: to anticoagulate or not. Clin Cardiol. 1993;16:529-530.
PUBMED
49. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making. 1992;12:239-249.
FREE FULL TEXT
50. Ezekowitz MD, James KE. Stroke prevention in Atrial Fibrillation II Study. Lancet. 1994;343:1508-1509.
PUBMED
51. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144-152.
PUBMED
52. O'Connell JE, Gray CS. Anticoagulation in patients with atrial fibrillation: use of warfarin dependent on local services. BMJ. 1993;307:1493.
FREE FULL TEXT
53. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154:1945-1953.
FREE FULL TEXT
54. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med. 1988;148:1733-1736.
FREE FULL TEXT
55. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
PUBMED
56. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989;262:2551-2556.
FREE FULL TEXT
57. Lepon J, Lair T. Functional Status of the Non-institutionalized Elderly: Estimates of ADL and IADL Difficulties. Rockville, Md: US Dept of Health and Human Services; 1990. US Dept of Health and Human Services publication 90-3462. 58. Bush TL, Miller SR, Criqui MH, Barrett-Connor E. Risk factors for morbidity and mortality in older populations: an epidemiologic approach. In: Hazzard WR, Bierman EL, Blass JP, Ettinger WH Jr, Halter JB, eds. Principles of Geriatric Medicine and Gerontology. 3rd ed. New York, NY: McGraw-Hill Book Co; 1994: 153-166. 59. Rhymes JA, McCullough LB. Nonaggressive management of the illnesses of severely demented patients: an ethical justification. J Am Geriatr Soc. 1994;42:686-687.
PUBMED
60. Luchins DJ, Hanrahan P. What is appropriate health care for end-stage dementia? J Am Geriatr Soc. 1993;41:25-30.
PUBMED
61. Nuland SB. How We Die: Reflections on Life's Final Chapter. New York, NY: Alfred A Knopf Inc; 1994. 62. Gillick M. Choosing Medical Care in Old Age: What Kind, How Much, When to Stop. Cambridge, Mass: Harvard University Press; 1994. 63. Volicer L, Collard A, Hurley A, Bishop C, Kern D, Karon S. Impact of special care unit for patients with advanced Alzheimer's disease on patients' discomfort and costs. J Am Geriatr Soc. 1994;42:597-603.
PUBMED
64. Hart RG, Halperin JL. Atrial fibrillation and stroke: revisiting the dilemmas. Stroke. 1994;25:1337-1341.
PUBMED
65. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45:704-706.
FREE FULL TEXT
66. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;151:1950-1953.
FREE FULL TEXT
67. Bath PM, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ. 1993;307:1045.
FREE FULL TEXT
68. Dow L, Bertagne B. Anticoagulation in patients with atrial fibrillation: underuse of warfarin is multifactorial. BMJ. 1993;307:1492-1493.
FREE FULL TEXT
69. Lip GY. Anticoagulation in patients with atrial fibrillation: no consensus among doctors. BMJ. 1993;307:1493.
FREE FULL TEXT
70. Taylor F, Ramsay M, Voke J, Cohen H. Anticoagulation in patients with atrial fibrillation: GPs not prepared for monitoring anticoagulation. BMJ. 1993;307:1493.
FREE FULL TEXT
71. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
FREE FULL TEXT
72. Lawson F, McAlister F, Ackman M, Ikuta R, Montague T. The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. J Am Geriatr Soc. 196;44:708-711.
73. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. BMJ. 1995;311:558-561.
FREE FULL TEXT
74. O'Connel JE, Gray CS. Atrial fibrillation and stroke prevention in the community. Age Aging. 1996;25:307-309.
FREE FULL TEXT
75. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156:2311-2316.
FREE FULL TEXT
76. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
FREE FULL TEXT
77. Middlekauff HR, Stevenson WG, Gornbein JA. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis. Arch Intern Med. 1995;155:913-920.
FREE FULL TEXT
78. Shakespeare J. Anticoagulation in patients with atrial fibrillation: GPs struggle to meet demand. BMJ. 1994;308:415.
FREE FULL TEXT
79. AGS Clinical Practice Committee. The use of oral anitcoagulants (warfarin) in older people. J Am Geriatr Soc. 1996;44:1112-1113.
PUBMED
80. Hylek EM, Skates SJ, Sheehan MA, Singer DE. AN analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
FREE FULL TEXT
81. White HD. Aspirin or warfarin for non-rheumatic atrial fibrillation? Lancet. 1994;343:683-684.
PUBMED
82. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469-473.
FREE FULL TEXT
|
